首页 >> 师资队伍 >> 正高 >> 正文

唐时幸

职称:三级教授;博士生导师;博士后合作导师

通讯地址:广州市南方医科大学公共卫生学院

办公电话:020-61648422

E-mail:tamgshixing@smu.edu.cn

所属科室:流行病学系

扩展字段01 职称:三级教授;博士生导师;博士后合作导师 扩展字段02 通讯地址:广州市南方医科大学公共卫生学院
扩展字段03 办公电话:020-61648422 扩展字段04 E-mail:tamgshixing@smu.edu.cn
扩展字段05 所属科室:流行病学系

学术任职

中国医药生物技术协会体外诊断技术分会副主任委员

最高学历

博士

研究方向

感染性疾病分子流行病学、新型检测技术研究与应用

科研项目

1)国家自然科学基金面上项目,“新发人持续性G病毒II型复制和感染细胞培养模型的建立及与HCV/HIV共感染的机制研究”,项目编号31872641, 起至时间2019.3.1-2022.12.31

2)十三.五计划艾滋病和病毒性肝炎等重大传染病防治科技重大专项 “传染病新型诊断技术研究与应用 (2018ZX10732401-003)”,2018-2020

3)广州市健康医疗协同创新重大专项“性传播疾病防控新技术研究与应用“(201704020219),2017-2020

4)广州市健康医疗协同创新重大专项“新发突发烈性传染病防控及治疗新技术研究”(201604020011),2016-2019

5)十二.五计划艾滋病和病毒性肝炎等重大传染病防治科技重大专项 “传染病现场快速诊断试剂的研制(2013ZX10004804)”,2013-2015

6)国家重大科学仪器专项 “核酸微流控富集单元及复杂基质处理应用开发(2012YQ090197)”,2012-2017

7)国家科技支撑计划项目 “疾病早期快速诊断技术和研发(2012BAI19B05)”,2012-2016


代表论文

1He X, Zeng B, Wang Y, Pang Y, Zhang M, Hu T, Liang Y, Kang M, Tang S.

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study. Frontiers in Immunology. 2023 Oct 17;14:1257360. doi:10.3389/fimmu.2023.1257360. eCollection 2023.


2Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, Zhang J, Liu J, Cheng M, Xie S, Luo M, Jiang J, Jiang Y, Tang S, He J. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China: A Cohort Study. Annals of Internal Medicine. 2022 Feb 1:M21-3509. doi: 10.7326/M21-3509


3Liang Y, Lin H, Zou L, Deng X, Tang S. Rapid detection and tracking of Omicron variant of SARS-CoV-2 using CRISPR-Cas12a-based assay. Biosensors & Bioelectronics. 2022 Feb 17; 205:114098


4Cheng Z, Yan H, Li Q, Ablan SD, Kleinpeter A, Freed EO, Wu H, Dzakah EE, Zhao J, Han Z, Wang H, Tang S. Enhanced Transmissibility and Decreased Virulence of HIV-1 CRF07_BC May Explain Its Rapid Expansion in China. Microbiology Spectrum. 2022 Aug 31;10(4):e0014622


5Chen S, Wu J, Yang X, Sun Q, Liu S, Rashid F, Dzakah EE, Wang H, Wang J, Gong P, Tang S. RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature. Microbiology Spectrum. 2022 Aug 18:e0272922. doi: 10.1128/spectrum.02729-22


6Dzakah EE, Zhao J, Wang L, Rashid F, Xu R, Yang L, Wan Z, Huang L, Wang H, Chen S, Ke W, Kyei F, Deng K, Tang S. Chlamydia trachomatis Stimulation Enhances HIV-1 Susceptibility through the Modulation of a Member of the Macrophage Inflammatory Proteins. Journal of Investigative Dermatology. 2021 Oct 15:S0022-202X(21)02318-6


7Yan H, Wu H, Xia Y, Huang L, Liang Y, Li Q, Chen L, Han Z, Tang S. Acquisition and transmission of HIV-1 among migrants and Chinese in Guangzhou, China from 2008 to 2012: Phylogenetic analysis of surveillance data. Infection Genetics Evolution. 2021 Aug;92:104870


8Wan Z, Liu J, Hu F, Shui J, Li L, Wang H, Tang X, Hu C, Liang Y, Zhou Y, Cai W, Tang S. Evidence that the second human pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication. Emerging Microbes & Infection. 2020; 9(1):485-495


9Wang H, Wan Z, Xu R, Guan Y, Zhu N, Li J, Xie Z, Lu A, Zhang F, Fu Y, Tang S. A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection. Clinical Infectious Diseases. 2018; 66(1):29-35


10Wang H, Wan Z, Sun Q, Wu Y, Li X, An X, Deng S, Zhu N, Ren X, Tong Y, Tang S. Second Human Pegivirus in Hepatitis C Virus-Infected and Hepatitis C Virus/HIV-1-Co-infected Persons Who Inject Drugs, China. Emerging Infectious Diseases 2018; 24(5):908-911


教材著作

CRISPR分子诊断技术原理及应用(2024,人民卫生出版社)

讲授课程

流行病学

成果奖励

1)浙江省千人计划特聘专家,浙江省政府,2015

2)广东省领军人才,广东省人民政府, 2012

3)美国食品药物管理局 (FDA) 杰出分析科学奖, 2011

4)美国食品药物管理局 (FDA) 杰出成就奖,2007

5)美国国家健康研究院 (NIH) 优秀研究人员奖 ,2001

6)中国人民解放军军队科技进步二等奖,1996


专利

1)检测新型冠状病毒变异株和亚型的方法(ZL 2021 1 0686862.4)

2)用于区分HIV-1新近与慢性感染的免疫吸附检测方法(ZL 2018 1 0600202.8


Baidu
map